Skip to main content
Premium Trial:

Request an Annual Quote

Clontech to Stop Selling RNase H Line After Settlement With Invitrogen

NEW YORK (GenomeWeb News) — Clontech will stop selling its RNase H minus reverse transcriptase products as part of a settlement reached last week with Invitrogen.
 
Invitrogen sued Clontech more than a decade ago for infringing two of its US patents — numbers 5,244,797 and 5,668,005 — that cover embodiments of the firm's reverse transcriptases. Invitrogen added two more of its US patents, numbers 6,063,608 and 5,405,776, to the suit later. All of the intellectual property relates to mutations that disable the RNase H activity of native reverse transcriptase
 
The settlement came after an undisclosed jury decision last week in a federal district court in Maryland. As part of the settlement, Clontech agreed that Invitrogen's patents in the case are "valid and enforceable."
 
Further details of the agreement were not disclosed.
 
Clontech is a wholly owned subsidiary of Takara Bio.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.